PAIRX BIO

PairX Bio Pte Ltd is developing next generation cancer immunotherapies targeting shared tumor-associated antigens derived from aberrantly spliced proteins. The foundational technology was developed at Duke-NUS Medical School in Prof. David Epstein’s lab.

HUMMINGBIRD BIOSCIENCE

Hummingbird Bioscience focuses on the discovery and early development of oncology drugs, from pre-clinical target validation to proof-of-concept (Phase II Clinical Trials).

ALTRUBIO

AltruBio is a clinical-stage biotech company focused on developing novel antibody therapeutics based on unique insights into T cell activation, to treat immunological diseases with high unmet medical needs, such as steroid-refractory acute GvHD.